05.31.23 -- How Research And Development Is Influencing The Future Of Clinical Trials

Charles Dickens’ famous opening line from his 1859 novel A Tale of Two Cities, “It was the best of times, it was the worst of times,” is a fitting description of the pharmaceutical space in recent years. Get a glimpse of how the industry has emerged from the tumultuous episode of the COVID-19 pandemic, stronger and emboldened.

The story of pharma R&D is an epic tale, so a literary theme for this year’s report was quite fitting. Although the COVID-19 chapter has not quite finished its final act, it appears the industry is emerging from this boisterous period recovered and enlivened. Find out if the 2023 pipeline was a page-turner.

This report looks at the industry’s success stories of 2022 — the drugs that were launched onto the market for the first time. It focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use.